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Geographical inequalities in lung cancer management and survival
in South East England: evidence of variation in access to oncology
services?
RH Jack*,1, MC Gulliford1, J Ferguson2 and H Møller3
1Department of Public Health Sciences, King’s College London, UK; 2Lambeth Southwark and Lewisham Health Authority, 1 Lower Marsh, London
SE1 7NT, UK; 3Thames Cancer Registry, King’s College London, UK
This study aimed to determine whether the management and survival of patients with lung cancer varied among 26 health authorities
in South East England. The Thames Cancer Registry identified patients diagnosed with lung cancer (ICD-10 codes C33–C34)
between 1995 and 1999. After excluding death certificate only patients, 32 818 (81%) patients were analysed. The proportions of
patients receiving active treatment varied among health authorities between 5 and 17% for non-investigative surgery, 4 and 17% for
any chemotherapy, 8 and 30% for any radiotherapy and 15 and 42% for any active treatment. One-year patient survival ranged from
11 to 34%. There was evidence of health authority level variation even after adjusting for case mix. Patients whose first hospital
attendance was at a radiotherapy centre were more likely to receive active treatment (OR 1.72, 95% CI 1.21–2.46), chemotherapy
(1.38, 1.06–1.79) or radiotherapy (1.86, 1.28–2.71). There was some evidence that patients whose first hospital attendance was at a
radiotherapy centre survived longer. This study shows there is geographical inequality in the treatment given to lung cancer patients
and patient survival in South East England. There was some evidence to suggest that these inequalities might be explained by
variations in access to oncology services. Future studies should investigate the pathways and barriers to specialist care in this
condition.
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Cancer is one of the main causes of death in Britain, and reducing
cancer mortality is a recognised national priority (Department of
Health, 1998a). There is great concern that survival rates with
cancer are relatively low in Britain when compared with Europe
(Janssen-Heijnen et al, 1998), and survival rates in Europe are
lower than in North America (Gatta et al, 2000). The management
of lung cancer is of particular concern because it is the most
common cancer, it is associated with older age and social
deprivation, survival rates are very low and treatment may often
be suboptimal (Department of Health, 1998b). However, there is
now good evidence that active treatment, either with surgery or
radiotherapy for non-small cell lung cancer, or with radiotherapy
or chemotherapy for small cell lung cancer, may prolong survival
and should not be denied to patients who might benefit (Brown
et al, 1996; Fergusson et al, 1996; Muers and Haward, 1996).
A number of reports have identified problems with the care of
patients with lung cancer. Patients presenting with symptoms
suggestive of lung cancer often experience delays at every stage of
the referral process. Billing and Wells (1996) found that the
median delay experienced by patients referred for surgery was 109
days, including 1 month before initial referral to a specialist, and 2
months before subsequent referral to a surgeon. Melling et al
(2002) found variations in the investigative procedures and
surgery received by patients with different modes of presentation
to hospitals (whether they were referred by their GP with or
without a chest X-ray, or presented themselves to the Accident and
Emergency Department). Recommended waiting times have been
shown to be achievable for most patients using a multidisciplinary
team (Deegan et al, 1998). Studies show around 70% of patients
receive a histological diagnosis, although this figure decreases with
age to 55% of patients aged 75–84 years (Kesson et al, 1998) and is
only 48% in patients not reviewed by a respiratory specialist
(Brown et al, 1996). A failure to evaluate the stage of the disease
accurately may have adverse effects. Patients may be denied
effective treatment if it is assumed that disease is widespread at
presentation, but thoracotomy should be avoided in patients with
unresectable disease. Some evidence suggests that the volume of
cases treated may be associated with the outcome (Selby et al,
1996; Hillner et al, 2000); some studies have suggested benefits
from nurse-run clinics (Department of Health, 1998c); other
studies suggest that more appropriate care may be provided by
specialist respiratory physicians (Brown et al, 1996). Kesson et al
(1998) found that patients who were originally referred to non-
respiratory physicians had a significantly longer delay before
surgery.
In a study of patients living in Scotland and diagnosed with lung
cancer in 1995 deprivation did not affect chances of receiving
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potentially curative treatment, but the most deprived quintile of
residents were significantly less likely to survive 3 years compared
to the least deprived quintile (Gregor et al, 2001). The health board
of residence was found to be associated with receiving thoracic
radiotherapy for those with non-small cell or unknown type of
lung cancer (Erridge et al, 2002).
Against this background, the English Department of Health has
developed a strategy to improve cancer services in England
(Department of Health, 1995). The strategy is establishing
subregional cancer networks whose aim is ‘to provide the means
by which healthcare professionals, treating cancer across an area
can jointly agree, implement and monitor the most appropriate
patterns of care for their patients’ (Northern and Yorkshire Cancer
Information Service, 2000). In June 1998, the Department of Health
published guidance on commissioning services for lung cancer
under the title ‘Improving Outcomes in Lung Cancer’ (Department
of Health, 1998b, c). The NHS Cancer Plan was launched in
September 2000 and aimed to tackle inequalities in quality of care
and treatment (Department of Health, 2000).
The present population-based study aimed to determine
whether there were variations in case mix, and inequalities in
case management, for lung cancer among 26 health authorities in
South East England from 1995 to 1999. We also wanted to find out
whether, after adjusting for case mix, there were area or health
service characteristics that were associated with more, or less,
favourable treatment patterns and with patient survival.
MATERIALS AND METHODS
Data
The Thames Cancer Registry supplied information on lung cancer
patients (ICD-10 codes C33–C34) resident in 26 health authorities
in South East England (Essex, Hertfordshire, London, Kent, Surrey
and Sussex), diagnosed between 1995 and 1999. Data on sex, age at
diagnosis, date of diagnosis, date of death (if applicable), basis of
diagnosis, histological type, stage of tumour, treatment and health
authority were also available. The basis of diagnosis was either
‘clinical’ or ‘histological’ and the histological category was further
divided into ‘small cell’, ‘non-small cell’ and ‘other and
unspecified’ types. The non-small cell category was made up of
squamous cell (55%), adenocarcinoma (28%), large cell (7%) and
other non-small cell carcinomas (10%). Standard TNM staging was
available for very few patients, so stage was classified as ‘localised’,
‘direct extension’, ‘local lymph nodes’, ‘metastases’ or ‘not known’.
These categories have been shown to be predictive of survival for
lung cancer patients (Thames Cancer Registry, 2000) and have
been used in previous studies (Gulliford et al, 1993a). Indicator
variables were specified to identify those subjects who received any
radiotherapy, any chemotherapy, any non-investigative surgery
(defined as either pneumonectomy or lobectomy) or any active
treatment (surgery, radiotherapy or chemotherapy).
From the dates of diagnosis and death, variables were created
indicating whether the patient had survived 1 or 3 years after
diagnosis. Survival times were censored on 31 December 1999.
This was the last year for which complete data were available. The
age standardised lung cancer incidence rate was calculated for each
district with reference to the European standard population. The
Townsend deprivation score was obtained from the Public Health
Common Data Set (Department of Health, 2001). We also
determined whether the first hospital trust visited as an inpatient
or outpatient was a radiotherapy centre.
Analysis
We initially tabulated case mix and treatment variables by year of
study. For each variable, we estimated the percentage of patients in
each category by health authority. Data are presented as the
median and range in order to document variation between health
authorities.
The data had a hierarchical structure with individual patients at
level one, and health authorities (or hospitals) at level two. Level
one units (patients) were nested within level two units (hospitals or
health authorities). Random effects (multilevel) logistic regression
models were fitted with health authority or hospital as a random
effect. This allowed for correlation in patient outcomes within
health authorities or hospitals. Analyses were performed using the
multilevel modelling package MLwiN (Rasbash et al, 2000).
Dependent variables included whether the patient received any
non-investigative surgery, any radiotherapy, any chemotherapy or
any active treatment. As explanatory variables the patient’s gender,
age at diagnosis (by 10 year group), basis of diagnosis, histological
type and tumour stage were fitted as fixed effects. Area and
hospital characteristics were also fitted simultaneously as fixed
effects. Similar models were used to investigate variation in 1- and
3-year survival between health authorities after adjusting for
treatment as well as case mix. When area and hospital
characteristics were included in the analysis, hospital first attended
was fitted as the level two variable instead of the health authority.
To assess whether completeness of information was influencing the
results the proportion of cases that were registered only on the
basis of a death certificate (DCO cases) in each health authority
was also fitted as a fixed effect.
RESULTS
There were 40 540 subjects with lung cancer registered in the 26
health authorities between 1995 and 1999. After excluding 13 cases
because of inconsistencies in the data and 7 709 ‘death certificate
only’ (DCO) registrations, 32 818 (81%) cases were analysed. The
percentage of DCO registrations decreased during the time of the
study from 25% in 1995 to 12% in 1999. The proportion of DCO
registrations varied from 10 to 28% in different health authorities.
Table 1 shows patient characteristics by study year. The
proportion of female patients significantly increased over time
(test for trend P¼ 0.004) from 36 to 39%. The proportion of
patients aged 64 and under remained approximately constant,
while the percentage aged 75 years and over increased. A
histological basis of diagnosis was recorded for about 75% of
patients throughout the study. The percentage of patients with
non-small cell lung cancer increased over time (test for trend
Po0.001) from 52 to 57%. More patients had their tumour staged
in 1999 than previously, with most patients being classified as
having either localised disease or metastases.
For the 26 health authorities, the age standardised incidence
rates ranged from 37 to 67 per 100 000, and the Townsend
deprivation index ranged between -5.5 (most affluent) and 12.2
(most deprived). Table 2 shows the extent of variation in case mix
among health authorities. The proportion with a histological
diagnosis ranged from 67 to 86%. The percentage of patients with
localised disease ranged from 16 to 50%, and the proportion with
unclassified tumour stage ranged from 16 to 54%.
Treatment
The extent of variation in treatment received by district of
residence is shown in Table 3. Over all years, 15% of patients
received any active treatment in one health authority compared
with 42% in another. The proportion of patients receiving specific
treatments also varied among health authorities, between 4 and
17% for any chemotherapy, 8 and 30% for any radiotherapy and 5
and 12% for non-investigative surgery. Non-investigative surgery
was defined as pneumonectomy or lobectomy, with all other
operations being classified as investigative surgery.
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Survival
Table 4 shows the median percentages of those who survived 1 and
3 years within the health authorities, over time. Only 2 years were
available for the 3-year survival and 4 years for the 1-year survival,
as the data were censored on 31 December 1999. The proportion
surviving 1 year ranged from 11 to 34% in different health
authorities and 3-year survival ranged from 7 to 17%. When DCO
patients were included in the analysis by adding a short period of
survival (1 day) to all cases, these figures decreased to 8– 24% for
1-year survival and 5 –12% for 3-year survival.
Figure 1 shows the standardised health authority level residuals
from the multilevel models with (A) any chemotherapy, (B) any
radiotherapy, (C) any non-investigative surgery, (D) any active
treatment, (E) 1-year survival and (F) 3-year survival as dependent
variables. The x-axis shows the rank of the health authorities for
that outcome after adjusting for case mix (and treatment in (E) and
(F)), and the y-axis represents the log odds of the outcome. The
vertical bars show 95% confidence intervals. The figure confirms
wide variation in treatment patterns among health authorities that
was not explained by adjusting for case mix, and that after
adjusting for case mix and treatment there was still evidence of
variation in patient survival among health authorities. There was
significant health authority level variation in all models, with
greatest variation in the model for any radiotherapy, adjusted for
case mix. As might be expected, the variation between health
authorities was much smaller in the survival models than the
models for treatment.
In order to evaluate whether area or hospital characteristics
explained variation in treatment or survival, we included the lung
cancer incidence rate, the Townsend deprivation score for the
health authority and whether the first hospital trust attended was a
radiotherapy centre simultaneously as additional fixed effects.
Results from these analyses (Table 5) showed that patients who
lived in health authorities with higher lung cancer incidence rates
were less likely to receive any active treatment, any radiotherapy or
any non-investigative surgery. Residents of a more deprived area
were less likely to receive any chemotherapy. If the first hospital
visited was a radiotherapy centre, patients were more likely
to receive any active treatment, any chemotherapy or any
Table 1 Frequencies (column %) of characteristics of non-DCO lung cancer patients diagnosed in South East England 1995–1999
Year of diagnosis
1995 1996 1997 1998 1999 All years
n % n % n % n % n % n %
Sex
Male 4007 64 3955 63 4122 63 4336 62 4165 61 20 585 63
Female 2298 36 2304 37 2380 37 2615 38 2636 39 12 233 37
Age at diagnosis groups (years)
o35 12 0 18 0 9 0 17 0 15 0 71 0
35–44 96 2 78 1 73 1 87 1 82 1 416 1
45–54 397 6 425 7 448 7 420 6 440 6 2130 6
55–64 1047 17 1057 17 1101 17 1154 17 1152 17 5511 17
65–74 2275 36 2327 37 2380 37 2412 35 2278 33 11 672 36
75–84 1989 32 1855 30 2016 31 2239 32 2183 32 10 282 31
85+ 489 8 499 8 475 7 622 9 651 10 2736 8
Basis of diagnosis
Clinical 1308 21 1189 19 1317 20 1360 20 1335 20 6509 20
Histological 4684 74 4816 77 4895 75 5277 76 5104 75 24 776 75
Other/not known 313 5 254 4 290 4 314 5 362 5 1533 5
Histological type
Small cell 863 14 879 14 837 13 899 13 865 13 4343 13
Non-small cell 3306 52 3294 53 3391 52 3783 54 3851 57 17 625 54
Other/not known 2136 34 2086 33 2274 35 2269 33 2085 31 10 850 33
Stage
Localised 1706 27 2078 33 2412 37 2608 38 2637 39 11 441 35
Direct extension 254 4 299 5 308 5 345 5 278 4 1484 5
Local lymph nodes 205 3 204 3 216 3 212 3 184 3 1021 3
Metastases 1776 28 1887 30 1830 28 2210 32 2240 33 9943 30
Not known 2364 37 1791 29 1736 27 1576 23 1462 21 8929 27
Deprivation quartile
1 (least deprived) 1715 27 1769 28 1808 28 1999 29 1911 28 9202 28
2 1739 28 1689 27 1821 28 1915 28 1910 28 9074 28
3 1292 20 1277 20 1313 20 1322 19 1329 20 6533 20
4 (most deprived) 1559 25 1524 24 1560 24 1715 25 1651 24 8009 24
First hospital visited a
radiotherapy centre 1882 30 2082 33 2137 33 2236 32 2203 32 10 540 32
Total 6305 6259 6502 6951 6801 32 818
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radiotherapy. There was no significant relation between survival
and deprivation or whether the first hospital trust attended was a
radiotherapy centre at the 5% level. However, if patients were
resident in areas with high lung cancer incidence they were less
likely to survive 1 and 3 years after diagnosis.
As age at diagnosis increased, patients were significantly less
likely to receive any treatment (P¼ 0.008), any chemotherapy
(Po0.001) or any non-investigative surgery (Po0.001), or survive
1 (Po0.001) and 3 (Po0.001) years. Females were significantly
more likely to receive any non-investigative surgery (P¼ 0.011)
and survive 1 (P¼ 0.005) and 3 (Po0.001) years after diagnosis.
Patients with metastases were significantly less likely to survive 1
(Po0.001) and 3 (Po0.001) years than those with localised
disease. Treatment received was strongly linked with 1- (Po0.001)
and 3-year (Po0.001) survival. All these associations were found
after adjusting for area, hospital and all other case-mix variables.
Patients do not always attend a hospital in their resident health
authority. Instead a cross classification occurs whereby hospitals
receive patients from several health authorities, and residents of a
health authority attend hospitals in various other health autho-
rities (Goldstein, 1995; Rasbash and Browne, 2001). By fitting
dummy variables MLwiN is able to model cross-classified
structures and take account of clustering by both hospital and
health authority. We therefore performed a sensitivity analysis by
fitting multilevel models allowing for cross classification in order
to evaluate whether this influenced our findings. In cross-classified
models, an increase in incidence was no longer significantly
associated at the 5% level with patients being less likely to receive
any treatment (OR 0.98, 95% CI 0.96– 1.00, P¼ 0.067), any
radiotherapy (OR 0.99, 95% CI 0.96– 1.01, P¼ 0.273), or survive
1 (OR 0.99, 95% CI 0.98–1.00, P¼ 0.100) or 3 (OR 0.99, 95% CI
0.98– 1.00, P¼ 0.107) years. The results from cross-classified
models were therefore more conservative. There was no difference
in the interpretation of the radiotherapy centre models when
adjusting for cross classification.
A second sensitivity analysis was performed by fitting the
proportion of DCO registrations as an additional explanatory
variable in the regression models. This gave small changes in odds
ratios and 95% confidence intervals that did not alter the
interpretation of the results. However, a unit increase in
deprivation score was not significantly associated with receiving
any surgery in the original model (OR 0.98, 95% CI 0.95–1.01,
P¼ 0.121), but after adjusting for proportion of DCO patients was
significantly associated (OR 0.96, 95% CI 0.93–1.00, P¼ 0025). The
level of significance for the association between incidence and
3-year survival was reduced when adjusting for proportion of DCO
registrations from P¼ 0.045 to 0.092, although the odds ratio and
95% confidence interval remained unchanged.
DISCUSSION
Main findings
There is evidence of geographical inequality in the treatment given
to lung cancer patients and in patient survival in South East
England. These differences are not readily explained by adjusting
Table 2 Distribution of characteristics within health authorities. Median
percentage and range of each category in health authorities, 1995–1999
Med % Range
Median number and range of patients 1226 621–2274
Sex
Male 63 58–65
Female 37 35–42
Basis
Clinical 20 12–30
Histological 75 67–86
Other/not known 4 1–10
Histological type
Small cell 13 10–15
Non-small cell 53 41–62
Other/not known 35 25–45
Stage
Localised 36 16–50
Direct extension 4 1–10
Local lymph nodes 3 1- 6
Metastases 30 24–36
Not known 25 16–54
Table 3 Median percentage and range of lung cancer patients with each
treatment by health authority, 1995–1999
Med % Range
None registered 20 14–25
Chemotherapy only (Chem) 4 3–9
Radiotherapy only (RT) 13 6–23
Non-investigative surgery only (S) 6 4–10
Chem + RT 4 1–7
S + Chem 0 0–1
S + RT 1 0–3
S + Chem + RT 0 0–1
Investigative surgery 51 34–71
Any Chem 8 4–17
Any RT 17 8–30
Any S 7 5–12
Any treatmenta 28 15–42
First hospital visited a radiotherapy centre 27 8–79
aAny treatment=any chemotherapy, radiotherapy or non-investigative surgery.
Table 4 Median percentage (range) of lung cancer patients surviving 1 or 3 years by health authority, including and excluding DCO patients
1995 1996 1997 1998 All years
Med % Range Med % Range Med % Range Med % Range Med % Range
Excluding DCOs
1-year survival 28 11–33 28 14–40 28 21–32 25 20–37 28 11–34
3-year survival 11 6–14 11 6–21 F F 11 7–17
Including DCOs
1-year survival 19 7–27 21 9–28 22 16–27 21 17–29 22 8–24
3-year survival 7 4–11 8 4–13 F F 8 5–12
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for variations in case mix or, in the case of survival, the treatment
received. Evidence of inequity is provided by the finding that
residents of districts with a high incidence rate for lung cancer are
less likely to receive any treatment after adjusting for deprivation,
first hospital attended and case mix. A possible clue to the source
of these inequalities and inequities is provided by the finding that
patients who are initially seen at a radiotherapy centre are more
likely to receive active treatment. However, a straightforward
interpretation must be qualified for several reasons.
Limitations of study
There were several concerns with the quality of the data. One of the
main problems was the exclusion of ‘death certificate only’
patients. These had to be removed from the analysis as they
included little case mix, and no treatment information. ‘Death
certificate only’ cases have shorter survival times than registered
patients, and therefore any survival times will be artificially high if
they are excluded (Pollock and Vickers, 1994). However, cancer
registry data appear to be reliable, with several studies finding high
levels of agreement between registry data and patients’ records
(Gulliford et al, 1993b; Stiller, 1997). The data did not contain any
information on comorbidity or performance status, which would
have an impact on both treatment received and survival.
A further problem for these analyses is the likelihood that data
quality and completeness would vary by health authority. There is
some evidence of variation in data quality across health authorities
indicated by variation in the proportion of DCO registrations
(range: 10 –28%) and the proportion of microscopically confirmed
cases (range: 67–86%). Twelve of the health authorities had a
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Figure 1 Health authority residuals and 95% confidence intervals against
rank for (A) any chemotherapy*, (B) any radiotherapy*, (C) any non-
investigative surgery*, (D) any treatment* (any chemotherapy, radio-
therapy or non-investigative surgery), (E) 1-year survivalw, (F) 3-year
survivalw.
*Adjusted for case mix; wAdjusted for case mix and treatment.
Table 5 Area and organisational characteristics associated with treat-
ment and survival. Odds ratios adjusted for sex, age group, histology and
stage of tumour, deprivation, lung cancer incidence, whether first hospital
attended was a radiotherapy centre and hospital fitted as random effect
OR 95% CI P-value
Any treatment
First hospital visited a radiotherapy centre 1.72 1.21–2.46 0.0027
Deprivation (Townsend score) 0.99 0.97–1.00 0.1784
Age standardised incidence (per 100 000) 0.98 0.97–0.99 o0.0001
Any chemotherapy
First hospital visited a radiotherapy centre 1.38 1.06–1.80 0.0179
Deprivation (Townsend score) 0.96 0.94–0.98 0.0010
Age standardised incidence (per 100 000) 1.01 0.99–1.02 0.4340
Any radiotherapy
First hospital visited a radiotherapy centre 1.86 1.28–2.71 0.0011
Deprivation (Townsend score) 1.01 0.99–1.03 0.2048
Age standardised incidence (per 100 000) 0.98 0.97–0.99 0.0034
Any non-investigative surgery
First hospital visited a radiotherapy centre 1.02 0.63–1.64 0.9383
Deprivation (Townsend score) 0.98 0.95–1.01 0.1206
Age standardised incidence (per 100 000) 0.97 0.96–0.99 0.0005
1-year survivala
First hospital visited a radiotherapy centre 1.20 0.97–1.50 0.0994
Deprivation (Townsend score) 1.01 1.00–1.03 0.1241
Age standardised incidence (per 100 000) 0.99 0.98–1.00 0.0320
3-year survivala
First hospital visited a radiotherapy centre 1.18 0.97–1.43 0.0947
Deprivation (Townsend score) 1.01 0.99–1.03 0.1692
Age standardised incidence (per 100 000) 0.99 0.98–1.00 0.0446
aAlso adjusted for active treatment.
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higher than the overall 19% proportion of DCO patients, but there
was no correlation between the proportion of DCO, stage not
known or microscopically confirmed cases and including the DCO
proportion as an additional explanatory variable had little effect on
the results.
Limitations of league tables
The limitations of performance league tables have been discussed
elsewhere (Goldstein and Spiegelhalter, 1996; Adab et al, 2002). We
have addressed these criticisms by adjusting for case mix and by
fitting statistical models which allowed for the correlation of
responses within areas or organisational units. We acknowledge
that adjustment for case mix is necessarily incomplete and, as
confounders may be misclassified, possibly biased. For these
reasons, we have chosen not to identify individual health
authorities in this report. The interpretation of the positive finding
with respect to initial hospital of treatment is especially difficult.
Patients whose condition is better, or whose disease is less severe,
may be selectively referred for active treatment. This could explain
why patients initially treated at a radiotherapy centre survived
longer. Nevertheless, these data suggest that the best chance of
obtaining active treatment is through referral to a radiotherapy
centre.
Comparison with other studies
The relation between specialisation, the volume of cases treated,
and the quality and outcomes of treatment have attracted
increasing attention in the study of health services. Concentrating
specialist services into centres of excellence offers economies of
scale, and may be associated with better case management of less
common conditions which are rarely seen. However, the potential
limitation of this approach is that geographical inequities in
service availability will be increased, and patients who live far from
specialist centres may encounter barriers to accessing services.
These barriers may result either from the costs and inconvenience
of travel, or from the reluctance of local professionals to make
referrals to a distant centre. Campbell et al (2000) found increasing
distance from a cancer centre was significantly associated with
poorer survival for lung cancer patients in Scotland.
The empirical evidence on the potential benefits of centralisa-
tion of specialist services is contradictory. Sowden et al (1995)
reviewed the literature relating to coronary artery surgery and
found that evidence in favour of concentrating services was weak
and mainly supported by small, poor–quality studies. Selby et al
(1996) reviewed the equivalent literature for cancer care and found
some evidence that patients treated at specialist centres with
higher caseloads had better outcomes. Specialist hospitals had
significantly better 5-year survival rates for patients aged under 75
years with breast, ovarian and rectal tumours than general
hospitals in East Anglia (Stockton and Davies, 2000). If initially
referred to a respiratory physician there was a significantly shorter
delay before surgery in Glasgow (Kesson et al, 1998), and lower
mortality was found when lung cancer resections were performed
by specialists in South Carolina (Silvestri et al, 1998).
Some studies have used hospitals’ patient volume as an indicator
for specialisation. Bach et al (2001) studied lung resection
procedures and found a positive association between number of
procedures and patients’ survival. Begg et al (1998) found high
surgery volume was significantly linked with lower 30-day
mortality for pancreatectomy, oesophagectomy, hepatic resection
and pelvic exenteration operations, but not pneumonectomy.
Another indication of specialisation is whether surgery takes place
at a teaching hospital. This was found to be significantly associated
with better 5-year survival in the USA (Bach et al, 2001). Teaching
hospital was not represented by radiotherapy centre in this study.
Implications of study findings
There were wide variations among districts in the use of different
treatment modalities with some variation in patient survival.
Studies in Yorkshire and Scotland also showed that rates of active
treatment, specialist management and survival (Northern and
Yorkshire Cancer Information Service, 1999) and thoracic radio-
therapy (Erridge et al, 2002) varied by district of residence.
Deprivation was related to lung cancer incidence (correlation
coefficient: 0.80), and patients resident in the most deprived health
authority were, on average, less likely to receive any active
treatment, chemotherapy or radiotherapy. There was evidence that
health authorities with higher incidence rates were less likely to
provide any treatment to their residents with lung cancer.
The need to standardise cancer care and treatment has been
recognised (Department of Health, 1995). The National Improving
Outcomes guidance for lung cancer was published in 1998
(Department of Health, 1998b, c) and the NHS Cancer Plan was
launched in September 2000 (Department of Health, 2000) but it is
very unlikely that these initiatives will have impacted on the
management of lung cancer in either 1998 or 1999. There is usually
a substantial time lag from publication of guidance to its
implementation and any subsequent improvement in outcomes.
These analyses should therefore be repeated after a suitable
interval in order to monitor changing patterns of treatment and
survival.
Conclusions
This study provides baseline data to evaluate the restructuring of
cancer services in the UK. It raises several questions concerning
the management of patients with lung cancer, and the organisation
of services for patients with this condition. Studies are needed to
find out whether current initiatives in the organisation of services
for this condition are reducing inequities in access at the level of
the health authority and the individual patient. Studies are also
needed to determine how patients gain access to specialist services
for lung cancer treatment and whether patients are referred
appropriately. A better understanding of the influence of the
preferences and priorities of patients and professionals in making
treatment decisions is also needed.
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